ID

37902

Beskrivning

A Study of Avastin (Bevacizumab) in Combination With Gemcitabine and Carboplatin as First Line Treatment in Patients With Triple Negative Metastatic Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01201265

Länk

https://clinicaltrials.gov/show/NCT01201265

Nyckelord

  1. 2019-08-29 2019-08-29 -
Rättsinnehavare

See clinicaltrials.gov

Uppladdad den

29 augusti 2019

DOI

För en begäran logga in.

Licens

Creative Commons BY 4.0

Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

Eligibility Breast Cancer NCT01201265

Eligibility Breast Cancer NCT01201265

Inclusion Criteria
Beskrivning

Inclusion Criteria

Alias
UMLS CUI
C1512693
female patients, >/= 18 years of age
Beskrivning

Gender | Age

Datatyp

boolean

Alias
UMLS CUI [1]
C0079399
UMLS CUI [2]
C0001779
metastatic breast cancer
Beskrivning

Secondary malignant neoplasm of female breast

Datatyp

boolean

Alias
UMLS CUI [1]
C0346993
estrogen receptor- , progesterone- and her2-negative disease
Beskrivning

Disease Estrogen receptor negative Progesterone receptor negative HER2 Negative

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C0279756
UMLS CUI [1,3]
C0279766
UMLS CUI [1,4]
C2348908
treatment-naïve for metastatic breast cancer
Beskrivning

Therapy naive Secondary malignant neoplasm of female breast

Datatyp

boolean

Alias
UMLS CUI [1,1]
C0919936
UMLS CUI [1,2]
C0346993
eastern cooperative oncology group (ecog) performance status 0-1
Beskrivning

ECOG performance status

Datatyp

boolean

Alias
UMLS CUI [1]
C1520224
adequate hematological, renal and liver function
Beskrivning

Hematologic function | Renal function | Liver function

Datatyp

boolean

Alias
UMLS CUI [1]
C0221130
UMLS CUI [2]
C0232804
UMLS CUI [3]
C0232741
Exclusion Criteria
Beskrivning

Exclusion Criteria

Alias
UMLS CUI
C0680251
prior first line treatment for metastatic breast cancer
Beskrivning

First line treatment Previous Secondary malignant neoplasm of female breast

Datatyp

boolean

Alias
UMLS CUI [1,1]
C1708063
UMLS CUI [1,2]
C0205156
UMLS CUI [1,3]
C0346993
cns metastasis
Beskrivning

CNS metastases

Datatyp

boolean

Alias
UMLS CUI [1]
C0686377
uncontrolled hypertension (> 170/95 mmhg)
Beskrivning

Uncontrolled hypertension | Blood pressure determination

Datatyp

boolean

Alias
UMLS CUI [1]
C1868885
UMLS CUI [2]
C0005824
evidence of bleeding diathesis, coagulopathy or hemorrhage at baseline
Beskrivning

Bleeding tendency | Blood Coagulation Disorder | Hemorrhage

Datatyp

boolean

Alias
UMLS CUI [1]
C1458140
UMLS CUI [2]
C0005779
UMLS CUI [3]
C0019080
history of other malignant disease within past 3 years, except for curatively treated basal cell carcinoma of the skin and carcinoma in situ of the cervix
Beskrivning

Cancer Other | Exception Curative treatment Basal cell carcinoma | Exception Curative treatment Carcinoma in situ of uterine cervix

Datatyp

boolean

Alias
UMLS CUI [1]
C1707251
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C1273390
UMLS CUI [2,3]
C0007117
UMLS CUI [3,1]
C1705847
UMLS CUI [3,2]
C1273390
UMLS CUI [3,3]
C0851140
prior therapy with gemcitabine or carboplatin in the metastatic setting. patients having received gemcitabine or carboplatin as part of adjuvant therapy are eligible, if recurrence was first documented >6 months after the last exposure to the drug(s)
Beskrivning

Prior Therapy | gemcitabine | Carboplatin | Neoplasm Metastasis | Adjuvant therapy

Datatyp

boolean

Alias
UMLS CUI [1]
C1514463
UMLS CUI [2]
C0045093
UMLS CUI [3]
C0079083
UMLS CUI [4]
C0027627
UMLS CUI [5]
C0677850
requirement of chronic use of immunosuppressive agents
Beskrivning

Requirement Immunosuppressive Agents chronic

Datatyp

boolean

Alias
UMLS CUI [1,1]
C1514873
UMLS CUI [1,2]
C0021081
UMLS CUI [1,3]
C0205191
hiv, hepatitis b or hepatitis c infection
Beskrivning

HIV Infection | Hepatitis B | Hepatitis C

Datatyp

boolean

Alias
UMLS CUI [1]
C0019693
UMLS CUI [2]
C0019163
UMLS CUI [3]
C0019196

Similar models

Eligibility Breast Cancer NCT01201265

Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Item Group
C1512693 (UMLS CUI)
Gender | Age
Item
female patients, >/= 18 years of age
boolean
C0079399 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
Secondary malignant neoplasm of female breast
Item
metastatic breast cancer
boolean
C0346993 (UMLS CUI [1])
Disease Estrogen receptor negative Progesterone receptor negative HER2 Negative
Item
estrogen receptor- , progesterone- and her2-negative disease
boolean
C0012634 (UMLS CUI [1,1])
C0279756 (UMLS CUI [1,2])
C0279766 (UMLS CUI [1,3])
C2348908 (UMLS CUI [1,4])
Therapy naive Secondary malignant neoplasm of female breast
Item
treatment-naïve for metastatic breast cancer
boolean
C0919936 (UMLS CUI [1,1])
C0346993 (UMLS CUI [1,2])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status 0-1
boolean
C1520224 (UMLS CUI [1])
Hematologic function | Renal function | Liver function
Item
adequate hematological, renal and liver function
boolean
C0221130 (UMLS CUI [1])
C0232804 (UMLS CUI [2])
C0232741 (UMLS CUI [3])
Item Group
C0680251 (UMLS CUI)
First line treatment Previous Secondary malignant neoplasm of female breast
Item
prior first line treatment for metastatic breast cancer
boolean
C1708063 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C0346993 (UMLS CUI [1,3])
CNS metastases
Item
cns metastasis
boolean
C0686377 (UMLS CUI [1])
Uncontrolled hypertension | Blood pressure determination
Item
uncontrolled hypertension (> 170/95 mmhg)
boolean
C1868885 (UMLS CUI [1])
C0005824 (UMLS CUI [2])
Bleeding tendency | Blood Coagulation Disorder | Hemorrhage
Item
evidence of bleeding diathesis, coagulopathy or hemorrhage at baseline
boolean
C1458140 (UMLS CUI [1])
C0005779 (UMLS CUI [2])
C0019080 (UMLS CUI [3])
Cancer Other | Exception Curative treatment Basal cell carcinoma | Exception Curative treatment Carcinoma in situ of uterine cervix
Item
history of other malignant disease within past 3 years, except for curatively treated basal cell carcinoma of the skin and carcinoma in situ of the cervix
boolean
C1707251 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C1273390 (UMLS CUI [2,2])
C0007117 (UMLS CUI [2,3])
C1705847 (UMLS CUI [3,1])
C1273390 (UMLS CUI [3,2])
C0851140 (UMLS CUI [3,3])
Prior Therapy | gemcitabine | Carboplatin | Neoplasm Metastasis | Adjuvant therapy
Item
prior therapy with gemcitabine or carboplatin in the metastatic setting. patients having received gemcitabine or carboplatin as part of adjuvant therapy are eligible, if recurrence was first documented >6 months after the last exposure to the drug(s)
boolean
C1514463 (UMLS CUI [1])
C0045093 (UMLS CUI [2])
C0079083 (UMLS CUI [3])
C0027627 (UMLS CUI [4])
C0677850 (UMLS CUI [5])
Requirement Immunosuppressive Agents chronic
Item
requirement of chronic use of immunosuppressive agents
boolean
C1514873 (UMLS CUI [1,1])
C0021081 (UMLS CUI [1,2])
C0205191 (UMLS CUI [1,3])
HIV Infection | Hepatitis B | Hepatitis C
Item
hiv, hepatitis b or hepatitis c infection
boolean
C0019693 (UMLS CUI [1])
C0019163 (UMLS CUI [2])
C0019196 (UMLS CUI [3])

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial